Congenital fetal heart block: A potential therapeutic role for intravenous immunoglobulin

Obstetrics and Gynecology

Volumn 116, Issue 2 PART 2, 2010, Pages 543-547

  David, Anna L ^a   Ataullah, Ifat ^b   Yates, Rob ^b   Sullivan, Ian ^b   Charles, Peter ^b   Williams, David ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; LA ANTIBODY; RO ANTIBODY;

ARTICLE; CASE REPORT; COMPLETE HEART BLOCK; CONGENITAL HEART BLOCK; DRUG EFFICACY; ECHOCARDIOGRAPHY; FETUS; FETUS ECHOGRAPHY; FETUS HEART RATE; HUMAN; MALE; PERINATAL PERIOD; PRIORITY JOURNAL; SINUS RHYTHM; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; FEMALE; FETAL DISEASES; HEART BLOCK; HEART DEFECTS, CONGENITAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RIBONUCLEOPROTEINS; SJOGREN'S SYNDROME;

EID: 77955129872     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181e75a4a     Document Type: Article

References (13)

1. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counter-immunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832-1835
2. Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexameth-asone Evaluation (PRIDE) prospective study. Circulation 2008;117:485-492
3. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated flucocorticoids to the natural history of autoantibody-associated congenital heart block. Arthritis Rheum 1999;42:2335-2345
4. Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticoste-roid therapy. Obstet Gynecol 1999;93:952-957
5. Kaaja R, Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticoste-roid therapy. Arthritis Rheum 2003;48:280-281
6. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994;120:544-551
7. Derksen RH, Meilof JF. Anti-Ro/SS-A and anti-La/SS-B auto-antibody levels in relation to systemic lupus erythematosus disease activity and congenital heart block: a longitudinal study comprising two consecutive pregnancies in a patient with systemic lupus erythematosus. Arthritis Rheum 1992;35: 953-959
8. Fleming GA, Bircher A, Kavanaugh-McHugh A, Liske MR. The cerebroplacental Doppler ratio predicts postnatal outcome in fetuses with congenital heart block. J Perinatol 2008;38: 791-796
9. Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr 1996;35:23-31.
10. Clancy RM, Neufing PJ, Zheng P, O'Mahony M, Nimmerjahn F, Gordon TP, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and-SSB/La antibodies in the pathogene-sis of congenital heart block. J Clin Invest 2006;116:2413-2422
11. Tran HB, Cavill D, Buyon JP, Gordon TP. Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum 2004;50:337-338
12. Lopes LM, Tavares GM, Damiano AP, Lopes MA, Aiello VD, Schultz R, et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation 2008;118:1268-1275
13. Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med 2009;265:653-662